A new study has reported the phase I results of AMG 133 (also known as maridebart cafraglutide), which is a bispecific molecule consisting of a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist antibody conjugated to two glucagon-like peptide 1 (GLP1) agonists. The researchers...
About the Phase 1 Study andFuture Development The randomized, double-blind, placebo-controlled single and multiple ascending dose study of AMG 133 enrolled people with a Body Mass Index (BMI) of ≥30.0 kg/m2 and ≤40.0 kg/m2 without other medical conditions. Participants were ran...
[1]Amgen presents new AMG 133 phase 1 clinical data at WCIRDC 2022 . Retrieved Dec 1, 2022. From网页链接 [2]Amgen Business Review Meeting. Retrieved Fe 8, 2022, from网页链接 @药明康德内容团队报道 免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代...
而在药物安全性方面,AMG 133的安全性与GLP-1受体激动剂及GLP-1/GIP受体双重激动剂类似,最常见的是胃肠道相关不良事件,包括恶心和呕吐,但其严重程度较轻微,且未观察到随着剂量增加的相关不良事件。 AMG 133不同于单一的GLP-1受体...
参考文献:1. Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb; 6(2): 290-303. 专家简介 李勇...
AMG 133不同于单一的GLP-1受体激动剂等药物,它结合多个分子,可以同时靶控多条作用通路,不仅减重,还可以减少进食,降低热量摄入,可谓是从源头杜绝肥胖可能性。 正值春节,很多人都开起了吃吃吃模式,正所谓每逢佳节胖三斤。但是“养膘容易,减肥难”!这种对于肥胖人群而言更为痛苦:吃了长肉 OR 只能眼巴巴看着别人大...
参考文献:1. Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb; 6(2): 290-303. 专家简介 李勇 复旦大学医学院内科学教授 ...
MedChemEMaridebartcafraglutideCat.No.:HY-164535CASNo.:2887445-76-1Synonyms:AMG133作⽤靶点:GLPReceptor作⽤通路:GPCR/GProtein储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性Maridebartcafraglutide⼀种抗体-肽结合物,作为GLP-1受体激动剂和...
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb;6(2):290-303. 品牌介绍:• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子...
最高研发阶段暂停临床1期 首次获批日期- 最高研发阶段(中国)- 特殊审评- 登录后查看时间轴 关联 1 项与AMG 513 相关的临床试验 NCT06585462 /Recruiting临床1期 A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Toler...